Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5736317 | Brain Research Bulletin | 2017 | 6 Pages |
Abstract
Tramadol is an analgesic agent that is mainly used to treat moderate to severe pain. There is evidence that tramadol may have antidepressant property. However, the mechanisms underlying the antidepressant effects of tramadol have not been elucidated yet. Considering that fact that N-methyl-d-aspartate (NMDA) receptor signaling may play an important role in the pathophysiology of depression, the aim of the present study was to investigate the role of NMDA receptor signaling in the possible antidepressant-like effects of tramadol in the mouse forced swimming test (mFST). We found that tramadol exerted antidepressant-like effects at high dose (40Â mg/kg, intraperitoneally [i.p.]) in the mFST. Co-administration of non-effective doses of NMDA receptor antagonists (ketamine [1Â mg/kg, i.p.], MK-801 [0.05Â mg/kg, i.p.], or magnesium sulfate [10Â mg/kg, i.p.]) with sub-effective dose of tramadol (20Â mg/kg, i.p.) exerted significant antidepressant-like effects in the mFST. The antidepressant-like effects of tramadol (40Â mg/kg) was also inhibited by pre-treatment with non-effective dose of the NMDA receptor agonist NMDA (75Â mg/kg, i.p.). Our data suggest a role for NMDA receptor signaling in the antidepressant-like effects of tramadol in the mFST.
Keywords
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Sattar Ostadhadi, Abbas Norouzi-Javidan, Mohsen Chamanara, Reyhaneh Akbarian, Muhammad Imran-Khan, Mehdi Ghasemi, Ahmad-Reza Dehpour,